ACON
Aclarion, Inc.
$3.57
+1.13%
$8.8M
No data for this timeframe.
Vol
Market Cap$8.8M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders1 funds
Inst. Value$33.00
Inst. Activity0 buys / 1 sells
Insider Activity4B / 0S
Insider Net $$50.9K
SEC Reports1
Press Releases5
Recent Activity
May 12, 2026
SEC
Four Aclarion insiders, including the CEO and three directors, collectively purchased $51K of stock in open-market trans
CLUSTER — Impact 6/10
May 12, 2026
Insider
Breidbart Scott bought 5,664 shares
Director @ $3.18 ($18.0K)
May 11, 2026
Insider
Ness Brent bought 6,289 shares
Chief Executive Officer @ $3.18 ($20.0K)
May 11, 2026
Insider
Neal David K bought 2,500 shares
Director @ $3.10 ($7.8K)
Inst.
UBS Group AG — EXIT
0 shares ($0.00)
Inst.
UBS Group AG — DOUBLED
1,729 shares ($13.0K)
Jun 3, 2026
Press
Aclarion announced an agreement with the Institute of Neuro Innovation (INI) in Los Angeles to expand availability of it
Impact 4/10
Jun 3, 2026
contract
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Gener
Price Targets
$7.50
+110.1% upside
Strong Buy
Current $3.57
Low $7.50
Median $7.50
High $7.50
1 analysts
$7.50
$7.50
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 29, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Mar 25, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.05 ▼ -10.5% | $-1.05 — $-1.05 | 62% YoY | 1 |
| Next Q | $-1.05 ▼ -5.0% | $-1.05 — $-1.05 | 64% YoY | 1 |
| Current FY | $-4.51 ▼ -3.2% | $-4.51 — $-4.51 | 64% YoY | 1 |
| Next FY | $-5.47 | $-5.47 — $-5.47 | -21% YoY | 1 |
Latest Reports
NEUTRAL
Press
4/10
Aclarion announced an agreement with the Institute of Neuro Innovation (INI) in Los Angeles to expand availability of it
Jun 3, 2026
BULLISH
CLUSTER
6/10
Four Aclarion insiders, including the CEO and three directors, collectively purchased $51K of stock in open-market trans
May 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BANK OF AMERICA CORP | $33.00 | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 12, 2026 | Breidbart Scott | BUY | $18.0K |
| May 11, 2026 | Ness Brent | BUY | $20.0K |
| May 11, 2026 | Neal David | BUY | $7.8K |
| May 6, 2026 | Wesemann William | BUY | $5.2K |
1 institutional holders with $33.00 total value (7 shares) as of 2025-Q4. Top holders: BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BANK OF AMERICA CORP /DE/ | 7 | $33.00 | 100.0% | DOUBLED +100.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | EXIT | 1,729 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 52 | 1,729 | +3225.0% | $13.0K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 4 | 8 | +100.0% | $61.00 | 2025-Q2 |
4 unique insiders with 4 transactions. Net insider value: $50.9K ($50.9K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 12, 2026 | Breidbart Scott | Director | BUY | 5,664 | $3.18 | $18.0K |
| May 11, 2026 | Ness Brent | Chief Executive Officer | BUY | 6,289 | $3.18 | $20.0K |
| May 11, 2026 | Neal David K | Director | BUY | 2,500 | $3.10 | $7.8K |
| May 6, 2026 | Wesemann William | Director | BUY | 1,562 | $3.30 | $5.2K |
1 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 6.0/10.
NEUTRAL
4/10
Aclarion announced an agreement with the Institute of Neuro Innovation (INI) in Los Angeles to expan
Jun 3, 2026
NEUTRAL
3/10
Aclarion announced that its Nociscan MRS technology was used in an award-winning research study expl
Jun 1, 2026
NEUTRAL
4/10
Aclarion announced a second commercial agreement with Weill Cornell Medicine for a prospective rando
May 5, 2026
NEUTRAL
3/10
Aclarion, Inc. announced a $2.5 million share repurchase program, funded by existing cash, to enhanc
Apr 22, 2026
NEUTRAL
4/10
Aclarion issued a shareholder letter from CEO Brent Ness highlighting progress in physician adoption
Mar 19, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 7 analysts: 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.50 mean target
+110.1% upside
Strong Buy (1.00)
$7.50 Low
$7.50 High
| Metric | Value |
|---|---|
| Current Price | $3.57 |
| Target Low | $7.50 |
| Target Mean | $7.50 |
| Target Median | $7.50 |
| Target High | $7.50 |
| # Analysts | 1 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.05 | $-1.05 | $-1.05 | 61.8% | -10.5% | 0↑ 1↓ | $0.0B | 55.3% | 1 |
| Next Q 2026-09-30 |
$-1.05 | $-1.05 | $-1.05 | 64.2% | -5.0% | 0↑ 1↓ | $0.0B | 105.9% | 1 |
| Current FY 2026-12-31 |
$-4.51 | $-4.51 | $-4.51 | 63.9% | -3.2% | 0↑ 1↓ | $0.0B | 78.3% | 1 |
| Next FY 2027-12-31 |
$-5.47 | $-5.47 | $-5.47 | -21.3% | — | — | $0.0B | 90.4% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.050 | |
| 7d ago | $-0.950 | -0.100 |
| 30d ago | $-0.950 | -0.100 |
| 60d ago | $-0.950 | -0.100 |
| 90d ago | $-3.240 | +2.190 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 29, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
contract
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Jun 1, 2026
fda
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune Biomarker Study
May 28, 2026
other
Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal
Aclarion Comments on Echo Lake Capital’s Letter and Unsolicited Proposal
May 7, 2026
other
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
May 6, 2026
other
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
May 5, 2026
fda
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
Apr 30, 2026
earnings
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
Apr 28, 2026
other
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
Apr 22, 2026
buyback
Aclarion Announces $2.5 Million Stock Repurchase Plan
Aclarion Announces $2.5 Million Stock Repurchase Plan
Apr 16, 2026
other
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
Apr 7, 2026
other
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
Mar 19, 2026
other
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
Mar 19, 2026
activist
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
Mar 17, 2026
other
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
Mar 12, 2026
other
Aclarion CEO Brent Ness to Attend LSI USA 2026
Aclarion CEO Brent Ness to Attend LSI USA 2026